top of page

Terry2™ Band starting trial in Canada

After a global slowdown in non-COVID19 clinical research activities, we are pleased to announce that the EASY-RAO study is finally underway and has started recruiting.

Nanostent is pleased to announce that the team of nurses under supervision of interventional cardiologists at Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) have started to randomize patients in the EASY-RAO Study. IUCPQ has > 25 years’ experience with transradial approach so cardiologists, nurses and staff have a long tradition to manage effectively radial or ulnar artery access site after all-kinds of clinical scenarios and procedures. After initial testing in Canada and Mexico, the Terry2™ band has consistently shown that it provides effortless, very comfortable, non-occlusive hemostasis in a shortened period of time.

This study aims to demonstrate the effectiveness of Terry2™ band to reduce radial artery occlusion (RAO) compared to single-artery compression, to provide improved comfort for patients, and to reduce workload for nurses.

After completion of the study in the next coming weeks, Nanostent plans to launch the Terry2 bands to the Canadian market, then Mexico and Latin-America in Q3 and Q4, 2020.

For more information, please contact us

Olivier F. Bertrand


Recent Posts

See All

Terry2™ Band launch in Canada and Mexico

With current recommendations aiming to reduce the radial artery occlusion (RAO) incidence < 5% after transradial approach, Nanostent has developed a unique dual artery hemostasis device. The Terry2™ b


bottom of page